Medicines & Healthcare products Regulatory Agency

12 November 2026

Dear colleagues,

I am pleased to share our results for the second quarter of 2026–27, alongside our priorities for the remainder of the calendar year.

This quarter's report demonstrates the progress we are making in building a more responsive MHRA. We delivered strong performance across our core regulatory services while accomplishing major milestones that shape how we regulate and support innovation in the years ahead.

Our Strategy to 2030 has set out our ambition to be a more modern, trusted regulator over the next five years, and our performance shows the strength of the foundation we are building from. We determined 99% of national medicines licence applications on time, assessed 97% of clinical trials and investigations within target and delivered 100% of written scientific advice on time, with scientific advice achieving a quality score of 9.7 out of 10.

We know sustaining this performance is critical to our success in our vision to deliver health and prosperity for all, through scientific excellence. As the science we regulate becomes more complex and demand for our services evolves, we need the right capability, capacity and financial model for the future. Our continuing work on statutory fees is an important part of our wider transformation, helping to ensure our regulatory services are sustainably resourced while driving further improvements in service predictability and timeliness. We are now analysing responses to our recent consultation ahead of publishing the government response and the future fee model for the MHRA.

This quarter also saw important progress in shaping a regulatory environment that can respond to rapidly evolving science and technology. The Government's acceptance of all 44 recommendations from the National Commission into the Regulation of AI in Healthcare provides a clear direction for translating ambition into regulatory reform and ensuring the UK is equipped to realise the opportunities of AI in healthcare.

In quarter 3, we will continue this progress. Alongside delivering our core services, we will bring together international regulatory and industry leaders at the DIA–MHRA Global Summit and London Life Sciences Week, launch the MHRA Women's Health Programme, take forward the first priority recommendations of the National Commission, publish our final guidance on individualised mRNA cancer therapies, and launch a new service to provider earlier advice to innovators on manufacturing quality requirements. We have already set out our new Public and Patient Involvement plan in this quarter, confirmed the indefinite recognition of all CE marked medtech on the GB market, and published guidance on our use of non-clinical data generated from outside the OECD system.

None of this can be achieved by the MHRA alone. I would like to thank industry, patients, healthcare professionals and our wider stakeholders for their continued engagement and support.

Lawrence Tallon
Chief Executive
Medicines and Healthcare products Regulatory Agency